<DOC>
	<DOCNO>NCT00449033</DOCNO>
	<brief_summary>Evaluation gemcitabine cisplatin combination either sorafenib placebo treatment patient advance Non-Small Cell Lung Cancer ( NSCLC )</brief_summary>
	<brief_title>A Phase III Randomized , Double-blind , Placebo Controlled Trial Comparing Efficacy Gemcitabine , Cisplatin Sorafenib Gemcitabine , Cisplatin Placebo First-Line Treatment Patients With Stage IIIb With Effusion Stage IV Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>During follow-up , determine one additional patient placebo still receive treatment 06 APR 2010 therefore 10 patient ' data report current CSR addendum , 6 sorafenib + GC group 4 placebo + GC group , ITT ( non-squamous ) population .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Age &gt; 18 year old Stage IIIB ( cytologically confirm malignant pleural pericardial effusion ) Stage IV histological cytological confirmation NSCLC nonsquamous cell carcinoma subtype . ( thoracentesis pericardiocentesis necessary biopsy original tumor available confirm diagnosis NSCLC ) . Patients least one measurable lesion . Lesions must measure CTscan MRI ( Magnetic resonance imaging ) accord Response Evaluation Criteria Solid Tumors ( RECIST , see Appendix 10.3 ) Life expectancy least 12 week Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior start first dose : Hemoglobin &gt; /= 9.0 g/dl ( &gt; /= 5.6 mmol/l ) Absolute neutrophil count ( ANC ) &gt; /= 1,500/mm3 Platelet count &gt; /= 100,000/Âµl Total bilirubin &lt; /= 1.5 x upper limit normal Alanine transaminase ( ALT ) Aspartate transaminase ( AST ) &lt; /= 2.5 x upper limit normal ( &lt; /= 5 x upper limit normal patient liver involvement cancer ) Alkaline Phosphatase &lt; /= 4 x upper limit normal PTINR ( Prothrombin Time International Normalized Ratio ) ( international normalize ratio PT ) /PTT ( Partial Thromboplastin Time ) &lt; 1.5 x upper limit normal Serum Creatinine &lt; /= 1.5 time upper limit normal Serum Creatinine Clearance &gt; /= 70ml/min Ability understand willingness sign write informed consent . A sign informed consent must obtain prior perform study specific procedure . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 . Excluded medical condition : Cardiac disease : Congestive heart failure &gt; class II NYHA ( New York Heart Association ) . Patients must unstable angina ( anginal symptom rest ) active coronary artery disease ( CAD ) , myocardial infarction within past 6 month Cardiac arrhythmia require antiarrhythmic therapy Uncontrolled hypertension define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management . History HIV ( Human immunodeficiency virus ) infection chronic hepatitis B C Active clinically serious infection ( &gt; grade 2 NCICTCAE ( National Cancer Institute Common Terminology Criteria Adverse Events ) version 3.0 ) Patients seizure disorder require medication ( steroids antiepileptic ) Known brain metastasis . Patients neurological symptom undergo CT scan/MRI brain exclude brain metastasis . History organ allograft Patients evidence history bleed diathesis coagulopathy Patients undergoing renal dialysis Cancer NSCLC within 5 year prior start study treatment EXCEPT cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor [ Ta ( Noninvasive tumor ) , Tis ( Carcinoma situ ) &amp; T1 ( Tumor invade lamina propria ) ] Uncontrolled hypertension define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management . Thrombotic embolic event cerebrovascular accident include transient ischemic attack within past 6 month Pulmonary hemorrhage/bleeding event &gt; Common Terminology Criteria Adverse Events ( CTCAE ) Grade 2 within 4 week first dose study drug Any hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 week first dose study drug Serious , nonhealing wound , ulcer , bone fracture Uncorrected dehydration Pregnant breastfeeding patient . Women childbearing potential must negative pregnancy test perform within 7 day start treatment . Both men woman enrol trial must use adequate birth control measure course trial . The definition effective contraception base judgment principal investigator designate associate . Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result Known suspect allergy investigational agent agent give association trial Any condition unstable could jeopardize safety patient compliance study Patients unable swallow oral medication Any malabsorption condition Patients hear impairment ( FOR GERMANY ONLY ) NSCLC patient squamous cell carcinoma diagnosis document either cytology biopsy . Excluded therapy medication , previous concomitant : Any prior systemic anticancer therapy include cytotoxic therapy , target agent , experimental therapy , adjuvant , neoadjuvant therapy NSCLC Concomitant use nephrotoxic drug , ototoxic drug , anticonvulsant , antigout treatment Radiotherapy study within 3 week start study drug . ( Palliative radiotherapy allow described Prior Concomitant Therapy section ) Radiotherapy study within 4 week start study drug . ( Palliative radiotherapy allow described Prior Concomitant Therapy section ) ( FOR FRANCE ONLY ) Major surgery , open biopsy significant traumatic injury within 4 week first dose study drug ( bronchoscopy allow ) Granulocyte colony stimulate factor ( GCSF ) Granulocyte macrophage colony stimulate factor ( GMCSF ) , within 3 week study entry ( growth factor may use study thereafter ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Non-Small Cell Lung Cancer ( NSCLC )</keyword>
	<keyword>Cancer</keyword>
</DOC>